<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01686997</url>
  </required_header>
  <id_info>
    <org_study_id>Elegance01</org_study_id>
    <nct_id>NCT01686997</nct_id>
  </id_info>
  <brief_title>Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities</brief_title>
  <acronym>Elegance</acronym>
  <official_title>'Effect of Long biLiopancrEatic Limb lenGth in lAparoscopic Roux-eN-Y Gastric Bypass on Weight Loss and Comorbidities in Patients With Morbid obEsity: a Prospective Randomized Control Trial'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Morbid obesity is an increasing medical problem in the western countries. It's related to
      comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia.
      The Roux-en-Y Gastric Bypass (RYGB) is an effective surgical therapy for morbidly obese
      patients. A part of these patients will have disappointing results, and have weight regain
      on the long term. Some studies show more weight reduction by increasing the biliopancreatic
      limb in patients with morbid obesity.

      The objective of this study is to investigate the effect of variations in the length of
      biliopancreatic limb on weight reduction in morbidly obese patients undergoing RYGB-surgery.
      We hypothesize that longer biliopancreatic limb results in more weight reduction.

      The study design is a prospective, randomized control trial. The patients will be randomized
      in 2 groups: a standard RYGB (short biliopancreatic limb) and long biliopancreatic limb
      RYGB.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Weight reduction</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>excess weight loss (%EWL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in comorbidities</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>diabetes mellitus, hypertension, hypercholesterolemia, arthrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>SF-36 and BAROS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications and re-operations</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>bleeding, wound infections, intra-abdominal abcess, anastomosis leakage, vitamine deficiencies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Primairy long biliopancreatic limb RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux limb 75 cm and Biliopancreatic Limb 150 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Redo Long biliopancreatic limb RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux limb 75 cm and Biliopancreatic limb 150 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primairy standard RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux limb 150 cm and Biliopancreatic limb 75 cm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Redo standard RYGB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Roux limb 150 cm and Biliopancreatic limb 75 cm</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y Gastric Bypass</intervention_name>
    <arm_group_label>Primairy long biliopancreatic limb RYGB</arm_group_label>
    <arm_group_label>Redo Long biliopancreatic limb RYGB</arm_group_label>
    <arm_group_label>Primairy standard RYGB</arm_group_label>
    <arm_group_label>Redo standard RYGB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient eligible for bariatric surgery according Fried guidelines

        Primary Gastric bypass

          -  BMI 35 - 40 with a comorbidity

          -  or BMI &gt; 40

        Redo- operation

          -  medical history: gastric sleeve/ mason / gastric band

          -  all BMI levels

        Exclusion Criteria:

          -  Exclusion criteria for bariatric surgery (Fried Guidelines)

          -  Patients with language problems that interveins to follow medical advises

          -  Genetic diseases that intervens to follow medical advises

          -  Chronic bowel diseases

          -  Nephrologic (MDRD &lt;30) of liver diseases (AST/ALT more than twice the norm)

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F.J. Berends, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric surgery</keyword>
  <keyword>Roux-en-Y Gastric Bypass</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
